The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET.
BACKGROUND
The term "posterior cortical atrophy" (PCA) refers to a clinical syndrome in which higher order visual processing is disrupted owing to a neurodegenerative disorder, the most commonly associated pathology being Alzheimer's disease.


OBJECTIVE
To map the topography of hypometabolic brain regions in a group of subjects with PCA who had undergone detailed neuropsychological characterisation.


METHODS
Resting cerebral metabolism was measured with ((18)F)fluorodeoxyglucose-positron emission tomography (FDG-PET) in patients with PCA (n = 6), typical Alzheimer's disease (n = 10), and healthy controls (n = 10). The data were analysed using statistical parametric mapping (SPM99) and region of interest techniques.


RESULTS
Clinically, the PCA subjects showed predominant visuospatial deficits (including features of Balint's syndrome) consistent with damage to the dorsal stream of visual processing. Compared with the controls, the PCA group showed marked glucose hypometabolism primarily affecting the posterior cerebral hemispheres (right worse than left). In addition, the PCA group showed two symmetrical areas of hypometabolism in the region of the frontal eye fields. Compared with typical Alzheimer's disease, the PCA group had selective hypometabolism in the occipito-parietal region (right much worse than left).


CONCLUSIONS
The neuropsychological and PET findings are consistent with damage predominantly to the dorsal stream of visual processing. Frontal eye field hypometabolism secondary to loss of input from the occipito-parietal region may be the mechanism for the ocular apraxia seen in Balint's syndrome.
Nestor
P J
PJ
University of Cambridge, Neurology Unit, Addenbrooke's Hospital, Cambridge, UK.
Caine
D
D
Fryer
T D
TD
Clarke
J
J
Hodges
J R
JR
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications / Q000503:physiopathology*; D001284:Atrophy; D001931:Brain Mapping; D016022:Case-Control Studies; D002540:Cerebral Cortex / Q000473:pathology*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014786:Vision Disorders / Q000209:etiology*; D014796:Visual Perception / Q000502:physiology
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18